In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Patent Battleground: Inter Partes Reviews Besiege Innovators

Executive Summary

Inter partes review, a new patent challenge proceeding, is increasingly being deployed against biopharma companies by generic manufacturers, biosimilar sponsors and hedge fund manager Kyle Bass. What the industry is doing to fight back.


Related Content

Congress Crafting Bill To Modify Patent Challenges In Wake Of Allergan-Mohawk Deal
Novartis Exelon Patch Patent Battle: PTAB Can Disagree With District Court
Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up
Patent Prognosis: Pfizer’s Chief IP Counsel On The Year Ahead
US Patent Battles May Resume Next Congress; Reps Press For IPR Reform
Pfizer Keeps IPR Winning Streak; Court Affirms Ruling On Tygacil Patent
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts